Immunotherapy revolutionizes cancer therapeutics but shows limited efficacy in hormone receptor-positive (HR<sup>+</sup>)/human epidermal growth factor receptor 2-negative (HER2<sup>-</sup>) breast cancer. Here, NR4A1 is linked to breast cancer.